Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The gut microbiome has an important role to play in ICI response7,8, as we also confirmed here”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Although we confirmed that the microbiome holds the potential to support the clinical practice for the treatment of patients with melanoma, as shown via fecal microbiota transplantation pilots7,8”
From Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma (2022) · cites this paper as [7]
In the citing paper
“Furthermore, two clinical trials unexpectedly found that FMT from ICI responders combined with anti-PD-1 therapy overcame resistance to PD-1 blockade in melanoma patients in 2021 [14, 15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“Currently, several lines of evidence from preclinical to clinical research have gradually established that the gut microbiota can modulate antitumor immunity and affect the efficacy of cancer immunotherapies, especially immune checkpoint inhibitors (ICIs).”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
In the citing paper
“The results showed that three of the ten patients showed tumor volume decline, including two partial responses (PR) and one complete response (CR) [15].”
From Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies (2022) · doi:10.1186/s13045-022-01273-9 · cites this paper as [15]
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Wickham, H. (2016) · Use R! · doi:10.1007/978-3-319-24277-4 · Cited by 33,115
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227
Conservation evaluation and phylogenetic diversity
Faith, D. P. (1992) · Biological Conservation · doi:10.1016/0006-3207(92)91201-3 · Cited by 5,693
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Self-citation
Cited by
Items 201–300 of 1,002
Crespin, A., Bescop, C. L., de Gunzburg, J., Vitry, F., Zalcman, G., Cervesi, J., & Bandinelli, P.-A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1075593 · Cited by 88
Visual Analysis of Colorectal Cancer Immunotherapy: A Bibliometric Analysis From 2012 to 2021
Ma, L., Ma, J., Teng, M., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.843106 · Cited by 72
The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma
Ernst, M. K., & Giubellino, A. (2022) · Biomedicines · doi:10.3390/biomedicines10040822 · Cited by 89
Advances in targeting tumor microenvironment for immunotherapy
Wang, L., Zhang, L., Zhang, Z., Wu, P., Zhang, Y., & Chen, X. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1472772 · Cited by 110
The Role of the Microbiome in the Etiopathogenesis of Colon Cancer
Tekle, G. E., Andreeva, N., & Garrett, W. S. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-025619 · Cited by 86
Beyond the Gut: The intratumoral microbiome's influence on tumorigenesis and treatment response
Zhang, H., Fu, L., Leiliang, X., Qu, C., Wu, W., Wen, R., Huang, N., He, Q., Cheng, Q., Liu, G., et al. (2024) · 癌症:英文版 · doi:10.1002/cac2.12597 · Cited by 78
Lin, A., Jiang, A., Huang, L., Yu, H., Zhang, C., Zhu, L., Mou, W., Liu, Z., Zhang, J., Cheng, Q., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2452277 · Cited by 81
Gut Microbiome in Anesthesiology and Pain Medicine
Minerbi, A., & Shen, S. (2022) · Anesthesiology · doi:10.1097/aln.0000000000004204 · Cited by 86
Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy
Wu, J., Wang, S., Zheng, B. J., Qiu, X., Wang, H., & Chen, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669150 · Cited by 83
Yang, F., Wang, J., Wang, Y., Liu, B., & Molina, J. R. (2021) · Cancers · doi:10.3390/cancers14010109 · Cited by 83
Gang, X., Yan, J., Li, X., Shi, S., Xu, L., Liu, R. M., Cai, L., Li, H., & Zhao, M. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217241 · Cited by 80
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 87
Chen, J., Levy, A., Tian, A.-L., Huang, X., Cai, G., Fidelle, M., Rauber, C., Ly, P., Pizzato, E., Sitterle, L., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.02.010 · Cited by 67
Cortellini, A., Ricciuti, B., Facchinetti, F., Alessi, J. V., Venkatraman, D., Dall’Olio, F. G., Cravero, P., Vaz, V. R., Ottaviani, D., Majem, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.08.1744 · Cited by 72
Uribe‐Herranz, M., Beghi, S., Ruella, M., Parvathaneni, K., Salaris, S., Κωστόπουλος, Ν., George, S. S., Pierini, S., Krimitza, E., Costabile, F., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.01.012 · Cited by 71
Cao, M., Deng, Y., Hao, Q., Yan, H., Wang, Q., Dong, C., Wu, J., He, Y., Huang, L., Xia, X., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02226-7 · Cited by 84
The Microbiome and Cancer: A Translational Science Review
Fernandez, E., Wargo, J. A., & Helmink, B. A. (2025) · JAMA · doi:10.1001/jama.2025.2191 · Cited by 95
Self-citationRandrian, V., Evrard, C., & Tougeron, D. (2021) · Cancers · doi:10.3390/cancers13123063 · Cited by 65
Immunotherapy in Pancreatic Adenocarcinoma: Beyond “Copy/Paste”
Hester, R., Mazur, P. K., & McAllister, F. M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0900 · Cited by 73
Čierniková, S., Ševčíková, A., Drgoňa, Ľ., & Mego, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188990 · Cited by 75
Gut microbiome for predicting immune checkpoint blockade-associated adverse events
Hu, M., Lin, X., Sun, T., Shao, X., Huang, X., Du, W., Guo, M., Zhu, X., Zhou, Y., Tong, T., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01285-9 · Cited by 77
Microbiota and body weight control: Weight watchers within?
Boscaini, S., Leigh, S., Lavelle, A., García‐Cabrerizo, R., Lipuma, T., Clarke, G. A., Schellekens, H., & Cryan, J. F. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101427 · Cited by 74
Lin, Y., Xie, M., Lau, H. C.-H., Zeng, R., Zhang, R., Wang, L., Li, Q., Wang, Y., Chen, D., Jiang, L., et al. (2024) · Med · doi:10.1016/j.medj.2024.10.007 · Cited by 82
Oh, B., Boyle, F. M., Pavlakis, N., Clarke, S. J., Eade, T., Hruby, G., Lamoury, G., Carroll, S. L., Morgia, M., Kneebone, A. B., et al. (2021) · Cancers · doi:10.3390/cancers13194824 · Cited by 78
Tumor-Associated Microbiome: Where Do We Stand?
Oliva, M., Mulet-Margalef, N., Ochoa-de-Olza, M., Napoli, S., Mas-Lloret, J., Laquente, B., Alemany, L., Duell, E. J., Nuciforo, P. G., & Moreno, V. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031446 · Cited by 65
Targeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer
Chang, A. E., Golob, J. L., Schmidt, T. M., Peltier, D. C., Lao, C. D., & Tewari, M. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2021.02.005 · Cited by 62
Wang, N., Wu, S., Huang, L., Hu, Y., He, X., He, J., Hu, B., Xu, Y., Rong, Y., Yuan, C., et al. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01117-x · Cited by 62
Current Surgical Indications for Non-Small-Cell Lung Cancer
Deboever, N., Mitchell, K. G., Feldman, H. A., Cascone, T., & Sepesi, B. (2022) · Cancers · doi:10.3390/cancers14051263 · Cited by 74
Lu, G., Wang, W., Li, P., Wen, Q., Cui, B., & Zhang, F. (2022) · Microbial Biotechnology · doi:10.1111/1751-7915.14074 · Cited by 62
Peiffer, L. B., White, J. R., Jones, C. B., Slottke, R., Ernst, S. E., Moran, A. E., Graff, J. N., & Sfanos, K. S. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100822 · Cited by 63
Ferrari, V., Cascio, A. L., Melacarne, A., Tanasković, N., Mozzarelli, A. M., Tiraboschi, L., Lizier, M., Salvi, M., Braga, D., Algieri, F., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.08.014 · Cited by 69
Zu, M., Liu, G., Xu, H., Zhu, Z., Zhen, J., Li, B., Shi, X., Shahbazi, M., Reis, R. L., Kundu, S. C., et al. (2024) · Advanced Materials · doi:10.1002/adma.202409138 · Cited by 66
Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies
Neil, V. M., & Lee, S. W. (2025) · Cancers · doi:10.3390/cancers17091408 · Cited by 74
Glioma and the gut–brain axis: opportunities and future perspectives
Dono, A., Nickles, J., Rodriguez-Armendariz, A. G., McFarland, B. C., Ajami, N. J., Ballester, L. Y., Wargo, J. A., & Esquenazi, Y. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac054 · Cited by 68
Self-citationFuture Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy
Airola, C., Severino, A., Porcari, S., Fusco, W. G., Mullish, B. H., Gasbarrini, A., Cammarota, G., Ponziani, F. R., & Ianiro, G. (2023) · Antibiotics · doi:10.3390/antibiotics12050868 · Cited by 82
Gut microbiome affects the response to immunotherapy in non‐small cell lung cancer
Ren, S., Feng, L., Liu, H., Mao, Y., & Yu, Z. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15303 · Cited by 76
Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect
Baruch, E. N., Wang, J., & Wargo, J. A. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0877 · Cited by 58
Self-citationThe gut microbiota promotes pain in fibromyalgia
Cai, W., Haddad, M., Haddad, R., Kesten, I., Hoffman, T., Laan, R., Westfall, S., Defaye, M., Abdullah, N. S., Wong, C., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.03.032 · Cited by 59
DeLeon, O., Mocanu, M., Tan, A., Sidebottom, A. M., Koval, J., Ceccato, H. D., Kralicek, S. E., Colgan, J. J., George, M. M. S., Lake, J., et al. (2025) · Cell · doi:10.1016/j.cell.2025.05.014 · Cited by 72
Mandal, K., Barik, G. K., & Santra, M. K. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02400-z · Cited by 77
The role of microbiome in pancreatic cancer
Li, J., Zhu, M., Kashyap, P., Chia, N., Tran, N. H., McWilliams, R. R., Bekaii‐Saab, T., & Ma, W. W. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09982-2 · Cited by 66
Hepatocellular Carcinoma: How the Gut Microbiota Contributes to Pathogenesis, Diagnosis, and Therapy
Luo, W., Guo, S., Zhou, Y., Zhao, J., Wang, M., Sang, L.-X., Chang, B., & Wang, B. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.873160 · Cited by 65
Strategies targeting tumor immune and stromal microenvironment and their clinical relevance
Hu, M., & Huang, L. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114137 · Cited by 67
Roles of microbiota in pancreatic cancer development and treatment
Cruz, M. S., Tintelnot, J., & Gagliani, N. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2320280 · Cited by 66
Novel strategies for modulating the gut microbiome for cancer therapy
Cho, Y. S., Han, K., Xu, J., & Moon, J. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115332 · Cited by 65
Su, J., Lin, X., Li, D., Yang, C.-M., Lv, S., Chen, X., Yang, X., Pan, B., Xu, R. P., Ren, L., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2347757 · Cited by 63
Cao, C., Yue, S., Lü, A., & Liang, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107321 · Cited by 67
Using mathematical modelling and AI to improve delivery and efficacy of therapies in cancer
Harkos, C., Hadjigeorgiou, A. G., Voutouri, C., Kumar, A. S., Stylianopoulos, T., & Jain, R. K. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00796-w · Cited by 79
Huang, C.-L., Li, M., Liu, B., Zhu, H., Dai, Q., Fan, X., Mehta, K. D., Huang, C. H., Neupane, P. C., Wang, F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642110 · Cited by 68
The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions
Kiousi, D. E., Kouroutzidou, A. Z., Neanidis, K., Karavanis, E., Matthaios, D., Pappa, A., & Galanis, Α. (2023) · Cancers · doi:10.3390/cancers15072101 · Cited by 76
Emerging clinical relevance of microbiome in cancer: promising biomarkers and therapeutic targets
Dai, J.-H., Tan, X.-R., Qiao, H., & Liu, N. (2023) · Protein & Cell · doi:10.1093/procel/pwad052 · Cited by 59
Gut microbiome therapy: fecal microbiota transplantation vs live biotherapeutic products
Kim, D.-Y., Lee, S.-Y., Lee, J., Whon, T. W., Lee, J., Jeon, C. O., & Bae, J. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2412376 · Cited by 67
Saadh, M. J., Allela, O. Q. B., Ballal, S., Mahdi, M. S., Chahar, M., Verma, R., Al-Hussein, R. K. A., Adil, M., Jawad, M. J., & Al-Nuaimi, A. M. A. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152398 · Cited by 74
Porcari, S., CICCARESE, C., Heidrich, V., Rondinella, D., Quaranta, G., Severino, A., Arduini, D., Buti, S., Fornarini, G., Primi, F., et al. (2026) · Nature Medicine · doi:10.1038/s41591-025-04189-2 · Cited by 67
Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome
Temraz, S. N., Nassar, F. J., Kreidieh, F., Mukherji, D., Shamseddine, A. I., & Nasr, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157800 · Cited by 62
Microbiota and Colorectal Cancer: From Gut to Bedside
Silva, M. G., Brunner, V., & Tschurtschenthaler, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.760280 · Cited by 66
The human microbiome in clinical translation: from bench to bedside
Bautista, J., Echeverría, C. E., Maldonado-Noboa, I., Ojeda-Mosquera, S., Hidalgo-Tinoco, C., & López-Cortés, A. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1632435 · Cited by 55
“These clinical responses were accompanied by shifts in immune cell infiltration and tumor microenvironment reprogramming, supporting a causal role for the microbiome in modulating therapeutic outcomes (Baruch et al., 2021; Davar et al., 2021).”
The critical role of tumor microbiome in cancer immunotherapy
Yang, L., Wang, Q., He, L., & Sun, X. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2301801 · Cited by 55
Microbiome bacterial influencers of host immunity and response to immunotherapy
Yousefi, Y., Baines, K. J., & Vareki, S. M. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101487 · Cited by 71
Di Luccia, B., Molgora, M., Khantakova, D., Jaeger, N., Chang, H.-W., Czepielewski, R. S., Helmink, B. A., Onufer, E. J., Fachi, J. L., Bhattarai, B., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adi5374 · Cited by 59
How microbiota improve immunotherapy
Ansaldo, E., & Belkaid, Y. (2021) · Science · doi:10.1126/science.abl3656 · Cited by 54
Tong, Y., & Lou, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1638352 · Cited by 68
Pinato, D. J., Li, X., Mishra-Kalyani, P. S., D’Alessio, A., Fulgenzi, C. A. M., Scheiner, B., Pinter, M., Wei, G., Schneider, J., Rivera, D. R. R., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100747 · Cited by 66
Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond
Ohtani, N., Kamiya, T., & Kawada, N. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000241 · Cited by 62
Turjeman, S., Rozera, T., Elinav, E., Ianiro, G., & Koren, O. (2025) · Cell · doi:10.1016/j.cell.2025.01.038 · Cited by 58
Self-citationImmune checkpoint inhibitors for the treatment of melanoma
Sabbatino, F., Liguori, L., Pepe, S., & Ferrone, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2038132 · Cited by 61
Current Trends and Challenges of Fecal Microbiota Transplantation—An Easy Method That Works for All?
Almeida, C., Oliveira, R., Baylina, P., Fernandes, R., Teixeira, F. G., & Barata, P. (2022) · Biomedicines · doi:10.3390/biomedicines10112742 · Cited by 56
Fecal microbiota transplantation in non-communicable diseases: Recent advances and protocols
Hamamah, S., Gheorghita, R. E., Lobiuc, A., Sîrbu, I. O., & Covașă, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1060581 · Cited by 60
Potential links between the microbiota and T cell immunity determine the tumor cell fate
Mohseni, A. H., Taghinezhad‐S, S., Casolaro, V., Lv, Z., & Li, D. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05560-2 · Cited by 55
Unraveling resistance to immunotherapy in MSI-high colorectal cancer
Heregger, R., Huemer, F., Steiner, M., Gonzalez-Martinez, A., Greil, R., & Weiss, L. (2023) · Cancers · doi:10.3390/cancers15205090 · Cited by 52
“Fecal microbiota transplantation from melanoma patients responding to ICIs to patients with primary resistance to ICIs is able to induce responses and/or long-lasting disease stabilization upon ICI rechallenge [95,96].”
BackgroundButyrate, a new microbiota-dependent player in CD8+ T cells immunity and cancer therapy?
Danne, C., & Sokol, H. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100328 · Cited by 57
Hamada, K., Isobe, J., Hattori, K., Hosonuma, M., Baba, Y., Murayama, M., Narikawa, Y., Toyoda, H., Funayama, E., Tajima, K., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1164724 · Cited by 60
Radiation injury and gut microbiota-based treatment
Wang, W., Cui, B., Nie, Y., Sun, L., & Zhang, F. (2023) · Protein & Cell · doi:10.1093/procel/pwad044 · Cited by 58
Jiang, S., Ma, W., Ma, C., Zhang, Z., Zhang, W., & Zhang, J. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2341717 · Cited by 57
Long-distance microbial mechanisms impacting cancer immunosurveillance
Zitvogel, L., Fidelle, M., & Kroemer, G. (2024) · Immunity · doi:10.1016/j.immuni.2024.07.020 · Cited by 58
The interactions between oral-gut axis microbiota and Helicobacter pylori
Chen, X., Wang, N., Wang, J., Liao, B., Cheng, L., & Ren, B. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.914418 · Cited by 61
Significance of Gut Microbiota and Short-Chain Fatty Acids in Heart Failure
Zhao, P., Zhao, S., Tian, J., & Liu, X. (2022) · Nutrients · doi:10.3390/nu14183758 · Cited by 58
Immunotherapy-related biomarkers: Confirmations and uncertainties
Catalano, M., Iannone, L. F., Nesi, G., Nobili, S., Mini, E., & Roviello, G. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104135 · Cited by 71
Liu, X., Lu, B., Tang, H. T., Jia, X., Zhou, Q., Zeng, Y., Gao, X., Chen, M., Xu, Y., Wang, M., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105427 · Cited by 58
Tumor microbiome: roles in tumor initiation, progression, and therapy
Zhang, S., Huang, J., Jiang, Z., Tong, H., Ma, X., & Liu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00248-9 · Cited by 63
Huang, M., Ji, Q., Huang, H., Wang, X., & Wang, L. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2486519 · Cited by 57
Microbiota-derived metabolites: Key modulators of cancer immunotherapies
Perl, M., Fante, M. A., Herfeld, K., Scherer, J. N., Poeck, H., & Orberg, E. T. (2025) · Med · doi:10.1016/j.medj.2025.100773 · Cited by 66
Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light
Zhang, J., Wu, K.-H., Shi, C., & Li, G. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-022-01027-2 · Cited by 56
Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma
Song, Y., Lau, H. C.-H., Zhang, X., & Yu, J. Q. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0394 · Cited by 78
An update on fecal microbiota transplantation for the treatment of gastrointestinal diseases
Waller, K. M. J., Leong, R. W. L., & Paramsothy, S. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15731 · Cited by 55
Harness the functions of gut microbiome in tumorigenesis for cancer treatment
Lee, M. (2021) · Cancer Communications · doi:10.1002/cac2.12200 · Cited by 50
Dees, K. J., Koo, H., Humphreys, J. F., Hakim, J. A., Crossman, D. K., Crowley, M. R., Nabors, B., Benveniste, E. N., Morrow, C. D., & McFarland, B. C. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab023 · Cited by 55
Role of the microbiome in oral cancer occurrence, progression and therapy
Li, Z., Liu, Y., & Zhang, L. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105638 · Cited by 55
Resistance to immune checkpoint inhibitors and the tumor microenvironment
Kawashima, S., & Togashi, Y. (2022) · Experimental Dermatology · doi:10.1111/exd.14716 · Cited by 55
Dóra, D., Bokhari, S. M. Z., Aloss, K., Takacs, P., Desnoix, J. Z., Szklenárik, G., Hurley, P. D., & Lohinai, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032769 · Cited by 51
Li, Y., Ye, Z., Zhu, J., Fang, S., Meng, L., & Zhou, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.844335 · Cited by 45
A BCG success story: From prevention of tuberculosis to optimal bladder cancer treatment
Lamm, D. L., & Morales, Á. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.08.026 · Cited by 56
Potential role of gut microbiota in prostate cancer: immunity, metabolites, pathways of action?
Zha, C., Peng, Z., Huang, K., Tang, K., Wang, Q., Zhu, L. J., Che, B., Li, W., Xu, S., Huang, T., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1196217 · Cited by 51
Mechanisms of Immunotherapy Resistance in Cutaneous Melanoma: Recognizing a Shapeshifter
Thornton, J., Chhabra, G., Singh, C. K., Guzmán‐Pérez, G., Shirley, C. A., & Ahmad, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.880876 · Cited by 62
Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy
Fan, S., Jiang, Z., Zhang, Z., Xing, J., Wang, D., & Tang, D. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05199-8 · Cited by 53
The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
Guo, C., Kong, L., Xiao, L., Liu, K., Cui, H., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01135-y · Cited by 48
Xia, L., Zhu, X., Wang, Y., & Lü, S. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217123 · Cited by 56
Tseng, C., Wong, S. H., Yu, J. Q., Lee, Y. Y., Terauchi, J., Lai, H., Luo, J., Kao, C., Yu, S., Liou, J., et al. (2025) · Gut · doi:10.1136/gutjnl-2024-334501 · Cited by 54
Gao, Y., Tan, Y.-J., & Fang, J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01026-w · Cited by 54
Lin, A., Huang, L., Jiang, A., Zhu, L., Mou, W., Li, Y., Zhang, C., Liu, Z., Zhang, J., Cheng, Q., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04183-y · Cited by 46
Metadata
- Authors
- Baruch, E. N., Youngster, I., Ben-Betzalel, G., Ortenberg, R., Lahat, A., Katz, L., Adler, K., Dick-Necula, D., Raskin, S., Bloch, N., Rotin, D., Anafi, L., Avivi, C., Melnichenko, J., Steinberg-Silman, Y., Mamtani, R., Harati, H., Asher, N., Shapira-Frommer, R., Brosh-Nissimov, T., Eshet, Y., Ben-Simon, S., Ziv, O., Khan, M. A. W., Amit, M., Ajami, N. J., Barshack, I., Schachter, J., Wargo, J. A., Koren, O., Markel, G., & Boursi, B.
- Affiliations
- Tel Aviv University (IL)
- The Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Tel-HaShomer, Israel.
- Sheba Medical Center (IL)
- Hadassah Medical Center (IL)
- Bar-Ilan University (IL)
- Institute of Pathology, Sheba Medical Center, Tel-HaShomer, Israel.
- University of Pennsylvania (US)
- Infectious Diseases Unit, Assuta Ashdod University Hospital, Ashdod, Israel.
- Azrieli Faculty of Medicine, Bar Ilan University, Safed, Israel.
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Baruch, Erez N.
- Markel, Gal
- Boursi, Ben
- ORCID
- Baruch, Erez N.
- Youngster, Ilan
- Ortenberg, Rona
- Lahat, Adi
- Katz, Lior
- Adler, Katerina
- Raskin, Stephen
- Bloch, Naamah
- Rotin, Daniil
- Anafi, Liat
- Avivi, Camila
- Melnichenko, Jenny
- Steinberg-Silman, Yael
- Mamtani, Ronac
- Harati, Hagit
- Asher, Nethanel
- Shapira-Frommer, Ronnie
- Eshet, Yael
- Khan, Md Abdul Wadud
- Amit, Moran
- Ajami, Nadim J.
- Barshack, Iris
- Schachter, Jacob
- Wargo, Jennifer A.
- Koren, Omry
- Markel, Gal
- Boursi, Ben
- Venue
- Science
- Published
- 2021-02-05
- Volume
- 371
- Issue
- 6529
- Pages
- 602-609
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W3111836013
- Semantic Scholar
- 20052eb45af3e9cf18b231c32b34bc26b96d2259
- Cited by
- 1,757
- References
- 65
- Citations by year
- 2026: 360 · 2025: 328 · 2024: 272 · 2023: 326 · 2022: 299 · 2021: 171
- FWCI
- 71.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- fecal microbiota transplantation, metastatic melanoma, anti-PD-1 therapy, gut microbiota, tumor microenvironment, immune cell infiltration, feasibility and safety
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Nivolumab, Adult, Female, Humans, Immunotherapy, Intestinal Mucosa, Male, Melanoma, Middle Aged, Skin Neoplasms, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Tumor Microenvironment, Transcriptome, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.